Kim Cheol Ju, Kwak Tae Young, Bae Min Hyeok, Shin Hwa Kyoung, Choi Byung Tae
Department of Korean Medicine, School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea.
Graduate Training Program of Korean Medical Therapeutics for Healthy Aging, Pusan National University, Yangsan, Republic of Korea.
J Pharmacopuncture. 2022 Dec 31;25(4):326-343. doi: 10.3831/KPI.2022.25.4.326.
Neurological disorders represent a substantial healthcare burden worldwide due to population aging. Solander (AG) and Schott (AT), whose major component is asarone, have been shown to be effective in neurological disorders. This review summarized current information from preclinical and clinical studies regarding the effects of extracts and active components of AG and AT (e.g., α-asarone and β-asarone) on neurological disorders and biomedical targets, as well as the mechanisms involved. Databases, including PubMed, Embase, and RISS, were searched using the following keywords: asarone, AG, AT, and neurological disorders, including Alzheimer's disease, Parkinson's disease, depression and anxiety, epilepsy, and stroke. Meta-analyses and reviews were excluded. A total of 873 studies were collected. A total of 89 studies were selected after eliminating studies that did not meet the inclusion criteria. Research on neurological disorders widely reported that extracts or active components of AG and AT showed therapeutic efficacy in treating neurological disorders. These components also possessed a wide array of neuroprotective effects, including reduction of pathogenic protein aggregates, antiapoptotic activity, modulation of autophagy, anti-inflammatory and antioxidant activities, regulation of neurotransmitters, activation of neurogenesis, and stimulation of neurotrophic factors. Most of the included studies were preclinical studies that used and models, and only a few clinical studies have been performed. Therefore, this review summarizes the current knowledge on AG and AT therapeutic effects as a basis for further clinical studies, and clinical trials are required before these findings can be applied to human neurological disorders.
由于人口老龄化，神经系统疾病在全球范围内构成了沉重的医疗负担。索兰德（AG）和肖特（AT），其主要成分是细辛脑，已被证明对神经系统疾病有效。本综述总结了来自临床前和临床研究的当前信息，这些信息涉及AG和AT的提取物及活性成分（如α-细辛脑和β-细辛脑）对神经系统疾病和生物医学靶点的影响，以及其中涉及的机制。使用以下关键词在包括PubMed、Embase和RISS在内的数据库中进行搜索：细辛脑、AG、AT和神经系统疾病，包括阿尔茨海默病、帕金森病、抑郁和焦虑、癫痫和中风。排除荟萃分析和综述。共收集到873项研究。在排除不符合纳入标准的研究后，共选择了89项研究。关于神经系统疾病的研究广泛报道，AG和AT的提取物或活性成分在治疗神经系统疾病方面显示出治疗效果。这些成分还具有广泛的神经保护作用，包括减少致病性蛋白质聚集体、抗凋亡活性、自噬调节、抗炎和抗氧化活性、神经递质调节、神经发生激活和神经营养因子刺激。纳入的研究大多是使用[具体模型未给出]模型的临床前研究，仅进行了少数临床研究。因此，本综述总结了关于AG和AT治疗效果的当前知识，作为进一步临床研究的基础，并且在这些发现能够应用于人类神经系统疾病之前需要进行临床试验。
